Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary... The vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate PRP), which is a high molecular weight polymer prepared from the Haemophilus influenzae type b strain 20,752.
- Primary indication
- Indicated for active immunization in pediatric patients 15 months through 4 years of age as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b.Curator reviewed · 2 structured indications
- First approval
- Canada, 2001 · United States, 2009
- Also known as
- Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine · Haemophilus influenzae type B-PRP and tetanus toxoid conjugate (PRP-T)
- Brand names
Resolves to
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account